Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
Copyright © 2013 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | No. (%) |
p-value | |
---|---|---|---|
No-PMRT group (n=78) | PMRT group (n=32) | ||
Median age (range, yr) | 49.5 (34.0-75.5) | 46.8 (32.4-68.9) | 0.081 |
≤50 | 42 (53.8) | 23 (71.8) | |
>50 | 36 (46.2) | 9 (28.2) | |
Tumor location | |||
Right | 42 (53.8) | 11 (34.4) | 0.083 |
Left | 36 (46.2) | 21 (65.6) | |
Medial | 52 (66.7) | 25 (78.1) | 0.234 |
Lateral | 14 (17.9) | 4 (12.5) | |
Center | 12 (15.4) | 3 (9.4) | |
Grade | |||
1 | 13 (16.7) | 4 (12.5) | 0.553 |
2 | 46 (58.9) | 22 (68.7) | |
3 | 19 (24.4) | 6 (18.8) | |
T stage | |||
1 | 28 (35.9) | 15 (46.9) | 0.298 |
2 | 50 (64.1) | 17 (53.1) | |
No. of positive nodes | |||
1 | 38 (48.7) | 16 (50.0) | 0.903 |
2 | 28 (35.9) | 11 (34.4) | |
3 | 12 (15.4) | 5 (15.6) | |
Median no. of dissected nodes (range) | 16 (4-38) | 16 (6-28) | |
≤15 | 37 (47.4) | 16 (50.0) | 0.807 |
>15 | 41 (52.6) | 16 (50.0) | |
Median percentage of positive nodes (range, %) | 11.8 (2.6-50.0) | 8.3 (4.5-33.3) | |
≤10 | 36 (46.2) | 20 (62.5) | 0.119 |
>10 | 42 (53.8) | 12 (37.5) | |
Lymphovascular invasion | |||
Yes | 12 (15.4) | 3 (9.4) | 0.125 |
No | 66 (84.6) | 29 (90.6) | |
Extracapsular extension | |||
Yes | 10 (12.9) | 3 (9.4) | 0.611 |
No | 68 (87.1) | 29 (90.6) | |
Resection margin (mm) | |||
≤5 | 18 (23.1) | 15 (46.9) | 0.013 |
>5 | 60 (76.9) | 17 (53.1) | |
Hormone receptor status | |||
Positive | 61 (78.2) | 25 (78.1) | 0.993 |
Negative | 17 (21.8) | 7 (21.9) | |
HER2 status | |||
Positive | 22 (28.2) | 11 (34.4) | 0.456 |
Negative | 56 (71.8) | 21 (65.6) | |
Molecular subtypes | |||
Luminal | 61 (78.2) | 25 (78.1) | 0.217 |
Triple negative | 8 (10.3) | 6 (18.7) | |
HER2-positive | 9 (11.5) | 1 (3.2) | |
Regimen of chemotherapy | |||
Adriamycin-based | 61 (78.2) | 26 (81.3) | 0.691 |
Non-adriamycin-based | 17 (21.8) | 6 (18.7) | |
Hormone therapy | |||
Yes | 61 (78.2) | 25 (78.1) | 0.993 |
No | 17 (21.8) | 7 (21.9) | |
Trastuzumab therapy | |||
Yes | 6 (7.7) | 2 (6.3) | 0.791 |
No | 72 (92.3) | 30 (93.7) |
Variable | 5-Year LRR rate (%) | p-value |
|
---|---|---|---|
Univariate analysis | Multivariate analysis | ||
Age (years) | |||
≤50 vs.>50 | 11.0 vs. 6.7 | 0.262 | 0.187 |
Tumor location | |||
Right vs. left | 9.5 vs. 8.8 | 0.959 | 0.867 |
Medial vs. lateral or center | 11.8 vs. 3.2 | 0.093 | 0.392 |
Histologic grade | |||
1-2 vs. 3 | 3.7 vs. 28.0 | <0.001 | 0.014 |
T stage | |||
1 vs. 2 | 4.6 vs. 12.5 | 0.099 | 0.152 |
No. of positive nodes | |||
1 vs. 2-3 | 7.4 vs. 10.8 | 0.26 | 0.602 |
No. of dissected nodes | |||
≤15 vs.>15 | 13.2 vs. 5.4 | 0.062 | 0.722 |
Percentage of positive nodes (%) | |||
≤10 vs.>10 | 7.2 vs. 11.1 | 0.215 | 0.558 |
Lymphovascular invasion | |||
Yes vs. no | 19.4 vs. 5.2 | 0.001 | 0.285 |
Extracapsular extension | |||
Yes vs. no | 46.2 vs. 4.2 | <0.001 | 0.001 |
Resection margin (mm) | |||
≤5 vs.>5 | 9.1 vs. 9.2 | 0.688 | 0.701 |
Molecular subtypes | |||
Luminal vs. triple negative vs. HER2-positive | 8.2 vs. 14.3 vs. 10.0 | 0.338 | 0.030 |
Regimen of chemotherapy | |||
Adriamycin-based vs. non-adriamycin-based | 6.4 vs. 8.7 | 0.162 | 0.733 |
Hormone therapy | |||
Yes vs. no | 8.9 vs. 10.5 | 0.382 | 0.125 |
Trastuzumab therapy | |||
Yes vs. no | 12.5 vs. 8.9 | 0.828 | 0.757 |
PMRT, postmastectomy radiotherapy; HER2, human epidermal growth factor receptor-2.
HER2, human epidermal growth factor receptor-2.